A comprehensive view of U.S. Food and Drug Administration (FDA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

China-based Hainan Yisheng Petrochemical, a subsidiary of Rongsheng Petrochemical, receives US FDA approval in July for its PCR PET for rPET food packaging

Eli Lilly dumps Innovent Biologic's Tyvyt PD-1 inhibitor after FDA rebuff, nixing high-profile Chinese cancer drug

Regeneron reports FDA has accepted its sBLA for Evkeeza evinacumab-dgnb for priority review; Evkeeza treats children with ultra-rare inherited homozygous familial hypercholesterolemia, a form of high cholesterol

FDA withdraws emergency use authorization of Eli Lilly’s bebtelovimab injectable COVID-19 antibody therapy, citing the therapy is most likely ineffective against Omicron BQ.1 and BQ.1.1; Lilly had supplied 60,000 doses of the drug to US government in Q3

AstraZeneca withdraws US COVID-19 vaccine application for Vaxzevria, shifts focus to antibody treatment Evusheld; Evusheld is approved in US to prevent COVID in immunocompromised people and in Europe as a preexposure prophylactic and as a treatment

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count